| Literature DB >> 31333348 |
Paweł Kwiatkowski1, Agata Pruss1, Helena Masiuk1, Magdalena Mnichowska-Polanowska1, Maciej Kaczmarek2, Stefania Giedrys-Kalemba1, Barbara Dołęgowska1, Hanna Zielińska-Bliźniewska3, Jurek Olszewski4, Monika Sienkiewicz3.
Abstract
INTRODUCTION: Staphylococcus aureus constitutes the most pathogenic species within the staphylococcal genus. Humans remain the major reservoirs of this pathogen which colonizes mostly anterior nares of healthy individuals. AIM: To investigate the effect of fennel essential oil (FEO) and trans-anethole (tA) on antibacterial activity of mupirocin (MUP) against S. aureus strains isolated from asymptomatic carriers.Entities:
Keywords: Staphylococcus aureus; fennel essential oil; mupirocin; trans-anethole
Year: 2019 PMID: 31333348 PMCID: PMC6640024 DOI: 10.5114/ada.2018.76425
Source DB: PubMed Journal: Postepy Dermatol Alergol ISSN: 1642-395X Impact factor: 1.837
Minimum inhibitory concentration (MIC) of fennel essential oil (FEO), trans-anethole (tA) and mupirocin (MUP) for S. aureus strains isolated from the asymptomatic carriers
| Strain number | Resistance phenotype | MIC of FEO | MIC of | MIC of MUP [μg/ml] |
|---|---|---|---|---|
| 1 | – | 2.0 | 3.0 | 0.25 |
| 2 | iMLSB | 2.5 | > 4.0 | 0.19 |
| 3 | iMLSB | 2.5 | > 4.0 | 0.38 |
| 4 | iMLSB | 1.5 | > 4.0 | 0.19 |
| 5 | iMLSB | 2.5 | > 4.0 | 0.38 |
| 6 | iMLSB | 2.5 | > 4.0 | 0.125 |
| 7 | iMLSB | 2.0 | > 4.0 | 0.125 |
| 8 | iMLSB | 2.0 | > 4.0 | 0.19 |
| 9 | – | 2.0 | > 4.0 | 0.125 |
| 10 | – | 2.5 | > 4.0 | 0.25 |
| 11 | – | 2.5 | > 4.0 | 0.125 |
| 12 | iMLSB | 1.5 | 4.0 | 0.125 |
| 13 | iMLSB | 1.5 | > 4.0 | 0.25 |
| 14 | – | 2.5 | 4.0 | 0.25 |
| 15 | – | 2.0 | > 4.0 | 0.19 |
| 16 | – | 2.5 | > 4.0 | 0.19 |
| 17 | – | 2.0 | > 4.0 | 0.19 |
| 18 | – | 2.0 | 4.0 | 0.19 |
| 19 | – | 2.0 | > 4.0 | 0.25 |
| 20 | – | 2.5 | >4.0 | 0.094 |
| 21 | – | 1.0 | > 4.0 | 0.125 |
| 22 | – | 2.5 | > 4.0 | 0.125 |
| 23 | – | 2.0 | > 4.0 | 0.125 |
| 24 | iMLSB | 1.0 | > 4.0 | 0.19 |
| 25 | – | 2.0 | > 4.0 | 0.125 |
| 26 | – | 2.0 | > 4.0 | 0.094 |
| 27 | – | 2.5 | > 4.0 | 0.19 |
| 28 | – | 2.5 | > 4.0 | 0.25 |
| 29 | – | 2.5 | > 4.0 | 0.19 |
| 30 | – | 1.5 | > 4.0 | 0.25 |
| 31 | – | 1.0 | > 4.0 | 0.125 |
| 32 | – | 1.5 | > 4.0 | 0.19 |
| 33 | iMLSB | 2.0 | > 4.0 | 0.125 |
| 34 | cMLSB | 2.5 | 3.5 | 0.125 |
| 35 | iMLSB | 2.5 | 3.5 | 0.25 |
| 36 | – | 1.5 | 3.5 | 0.125 |
| 37 | iMLSB | 2.0 | 3.5 | 0.19 |
| 38 | – | 2.0 | 3.5 | 0.125 |
| 39 | iMLSB | 1.5 | > 4.0 | 0.125 |
| 40 | iMLSB | 2.0 | 3.0 | 0.125 |
| 41 | iMLSB | 2.0 | 3.5 | 0.19 |
| 42 | cMLSB | 2.0 | > 4.0 | 0.094 |
| 43 | iMLSB | 2.0 | > 4.0 | 0.125 |
p < 0.0001.
iMLSB – inducible macrolide-lincosamide-streptogramin B resistance phenotype, cMLSB – constitutive macrolide-lincosamide-streptogramin B resistance phenotype.
Figure 1Determination of the optimal concentration of fennel essential oil (FEO) and trans-anethole (tA) affecting the minimum inhibitory concentration (MIC) of mupirocin (MUP) against S. aureus ATCC® 29213™. Concentration lower than 0.064 μg/ml (*), Mueller-Hinton Agar (MHA)
Figure 2Minimum inhibitory concentration of mupirocin against S. aureus ATCC® 29213™: A – Mueller-Hinton Agar (MHA) supplemented with 1% (v/v) Tween® 80 without fennel essential oil (FEO) or trans-anethole (tA), B – MHA supplemented with 1% (v/v) Tween® 80 and 0.75% FEO, C – MHA supplemented with 1% (v/v) Tween® 80 and 1.5% tA